There's a significant connection between obstructive sleep apnea (OSA) and type 2 diabetes, with many individuals experiencing both conditions simultaneously. Studies have shown that approximately seven in ten individuals with type 2 diabetes also have OSA.
“By leveraging Continuous Glucose Monitoring (CGM) and Continuous Positive Airway Pressure (CPAP) therapy, individuals can effectively manage both diabetes and sleep apnea, leading to improved health outcomes and a higher quality of life,” says Robert Miller, Apria's Vice President of Sleep Business.
For many years, managing diabetes required frequent finger sticks to monitor blood sugar levels. This method provided only a snapshot of glucose levels during testing, often missing daily fluctuations. The introduction of the Continuous Glucose Monitoring (CGM) has revolutionized diabetes care.
A Continuous Glucose Monitor (CGM) involves a tiny sensor that's inserted into the arm or abdomen. This sensor measures glucose levels in the interstitial fluid and transmits readings every five or so minutes. This near real-time data offers a comprehensive view of glucose trends throughout the day, allows for patients to be alerted when their blood sugar levels drop or spike, and enables proactive management of blood sugar levels.
The relationship between diabetes and sleep apnea is bidirectional, meaning both conditions influence the other. Poorly managed diabetes can exacerbate OSA symptoms, and on the flip side, untreated sleep apnea can lead to poorer glucose control.
When breathing pauses during sleep, carbon dioxide levels increase in the blood, leading to several complications:
Addressing both sleep apnea and diabetes can significantly improve health outcomes.
CPAP therapy involves using a machine that delivers a steady stream of pressurized air through a mask to keep the upper airways open during sleep. This prevents the pauses in breathing that characterize OSA, thereby reducing carbon dioxide buildup and improving insulin sensitivity.
CGM is particularly beneficial for diabetes management. It monitors glucose levels overnight and alerts users to any significant spikes or dips. Maintaining stable blood sugar levels can reduce the severity of OSA symptoms, creating a positive feedback loop for overall health.
Understanding and managing the interplay between sleep apnea and diabetes is crucial. Continuous Glucose Monitoring (CGM) and Continuous Positive Airway Pressure (CPAP) therapy offer practical tools for managing these conditions. By improving sleep quality and maintaining stable glucose levels, individuals can achieve better health outcomes and enhance their quality of life.
If you have diabetes and struggle with sleep apnea, Continuous Glucose Monitoring (CGM) could be a key player in your health management. Explore Byram Healthcare's CGM options and see if you qualify for this innovative technology.
References
Banghøj, Anne Margareta, Christoffer Krogager, Peter Lommer Kristensen, Klavs Würgler Hansen, Esben Laugesen, Jesper Fleischer, Simon Lebech Cichosz, et al. “Effect of 12-Week Continuous Positive Airway Pressure Therapy on Glucose Levels Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes and Obstructive Sleep Apnoea; a Randomized Controlled Trial.” Endocrinology, diabetes & metabolism, August 8, 2020.
Cleveland Clinic. “Sleep Apnea Can Make Managing Diabetes More Difficult: What You Need to Know.” Cleveland Clinic, June 27, 2024.
“Continuous Glucose Monitors.” Byram Healthcare. Accessed July 19, 2024.
Dawson, Arthur, Lawrence E. Kline, Daniel F. Kripke, John W. Cronin, Farhad F. Shadan, George Dailey, Richard T. Loving, and Susan L. Abel. “CPAP Therapy of Obstructive Sleep Apnea in Type 2 ...” Journal of Clinical Sleep Medicine, December 15, 2008.
Kingshott, Ruth. “Patients with Type 2 Diabetes or Hypertension Must Be Evaluated for Sleep Apnea.” American Academy of Sleep Medicine – Association for Sleep Clinicians and Researchers, August 23, 2017.
Muraki, Isao, Hiroo Wada, and Takeshi Tanigawa. “Sleep Apnea and Type 2 Diabetes.” Journal of diabetes investigation, September 9, 2018.
LEGAL DISCLAIMER: Material in this newsletter is provided for general health education and informational purposes and to provide references to other resources only; it may not apply to you as an individual. While Apria Healthcare believes that the information provided through this communication is accurate and reliable, Apria Healthcare cannot and does not make any such guarantee. It is not intended to be a replacement for professional medical advice, evaluation, diagnosis, services or treatment (collectively, “medical treatment”). Please see your healthcare provider for medical treatment related to you and your specific health condition(s). Never disregard medical advice or delay seeking medical care because of something you have read on or accessed through this website. Reading this newsletter should not be construed to mean that you have a healthcare provider/patient relationship.